Table_2_A Regenerative Approach to Canine Osteoarthritis Using Allogeneic, Adipose-Derived Mesenchymal Stem Cells. Safety Results of a Long-Term Follow-Up.DOCX

Mesenchymal stem cells (MSC) are emerging as an effective therapeutic tool in treating canine osteoarthritis (OA). In this report, we focused on the questions of whether MSC transplantation has long-term beneficial effects for the improvement in motion and also evaluated the safety of MSC injection. Visceral adipose tissue, a surgical waste obtained during routine ovariectomy served as a source of allogeneic MSCs and used to treat OA. Altogether, fifty-eight dogs were transplanted in the study suffering from OA in the elbow (42 animals), hip (5), knee (8), ankle (2), and hock (1). The effect of MSC transplantation was evaluated by the degree of lameness at a 4-5-years follow-up period based on the owners' subjective observations. The results showed that 83% of the OA patients improved or retained improvement in lameness. Clinical safety of the treatment was assessed by evaluating the coincidence of tumors or other diseases and other adverse reactions (such as local inflammation) after MSC cell therapy. Two incidences of local inflammation for <1 week at the site of injection were reported. No other adverse reactions were detected post-treatment. Sixteen dogs died during the study, 4 due to cancer and 12 due to other diseases, diagnosed by veterinarians. Overall, our survey suggests that MSC transplantation has long-term beneficial effects in reducing lameness. Moreover, no enrichment in a specific cause of death was observed in the transplanted animals, compared to reported literature. Our data suggest that MSC treatment could be an effective and safe long-term therapy for canine OA.

间充质干细胞（Mesenchymal stem cells, MSC）正成为治疗犬骨关节炎（canine osteoarthritis, OA）的有效治疗手段。本研究聚焦于间充质干细胞移植能否改善犬运动功能并产生长期益处，同时评估了间充质干细胞注射的安全性。本研究取常规卵巢切除术术中获取的手术废弃内脏脂肪组织作为异体间充质干细胞（allogeneic MSCs）的来源，用于治疗犬骨关节炎。本研究共纳入58只患骨关节炎的受试犬，其中肘关节受累42只、髋关节5只、膝关节8只、踝关节2只、跗关节1只。基于犬主的主观观察，在受试犬接受移植后的4~5年随访期内，通过跛行程度评估间充质干细胞移植的治疗效果。结果显示，83%的骨关节炎患犬跛行症状得到改善或维持改善状态。本研究通过评估间充质干细胞治疗后肿瘤及其他疾病、注射部位局部炎症等不良反应的发生情况，评估治疗的临床安全性。研究中共报告2例注射部位局部炎症反应，持续时长均不足1周，未检测到其他治疗后不良反应。本研究期间共有16只受试犬死亡，其中4只因癌症死亡，12只因其他疾病死亡，死由兽医诊断确认。总体而言，本研究结果表明，间充质干细胞移植可长期改善犬骨关节炎患犬的跛行症状。与已发表文献报道相比，本研究中移植受试犬的死亡原因未出现特定富集趋势。本研究数据提示，间充质干细胞治疗或可成为一种安全有效的犬骨关节炎长期治疗方案。